Investors

Investors

Corporate Profile

ERYTECH is a clinical-stage biopharmaceutical company developing innovative red blood cell-based therapeutics for severe forms of cancer and orphan diseases. Leveraging its proprietary ERYCAPS platform, which uses a novel technology to encapsulate drug substances inside red blood cells, ERYTECH is developing a pipeline of product candidates for patients with high unmet medical needs. ERYTECH’s primary focus is on the development of product candidates that target the altered metabolism of cancer cells by depriving them of amino acids necessary for their growth and survival.

The Company’s lead product candidate, eryaspase, which consists of L-asparaginase encapsulated inside donor-derived red blood cells, targets the cancer cell’s altered asparagine and glutamine metabolism. Eryaspase is in Phase 3 clinical development for the treatment of second-line pancreatic cancer and in Phase 2 for the treatment of first-line triple-negative breast cancer. An investigator-sponsored Phase 2 study in second-line acute lymphoblastic leukemia is ongoing in the Nordic countries of Europe.

ERYTECH produces its product candidates for treatment of patients in Europe at its GMP-approved manufacturing site in Lyon, France, and for patients in the United States at its recently opened GMP manufacturing site in Princeton, New Jersey, USA.

Stock Quote

Exchange
Price
Change (%)
Volume
Data as of
Exchange
Price
Change (%)
Volume
Data as of
More >>

Recent News

Date Title and Summary Additional Formats
Toggle Summary ERYTECH Announces Collaboration with Queen’s University to Advance its Product Candidate for Rare Metabolic Disorders
LYON, France --(BUSINESS WIRE)--Jul. 12, 2017-- Regulatory News: ERYTECH Pharma (Paris:ERYP) (ADR:EYRYY) (Euronext Paris - ERYP), a French clinical-stage biopharmaceutical company developing innovative therapies for rare forms of cancer and orphan diseases, today announced that it has entered into
View HTML
Toggle Summary ERYTECH Announces Commencement of Trading of ADSs on Nasdaq and Full Exercise of Underwriters’ Option, Bringing Gross Proceeds of Global Offering to $144 Million
Base deal of $125 million in gross proceeds from specified categories of specialized investors closed on November 14, 2017 . Announced full exercise of underwriters’ option to purchase additional American Depositary Shares (ADSs) and Ordinary Shares, with closing expected to take place on or about
View HTML
Toggle Summary ERYTECH Announces Commencement of Trading of ADSs on Nasdaq and Full Exercise of Underwriters’ Option, Bringing Gross Proceeds of Global Offering to $144 Million
Base deal of $125 million in gross proceeds from specified categories of specialized investors closed on November 14, 2017 . Announced full exercise of underwriters’ option to purchase additional American Depositary Shares (ADSs) and Ordinary Shares, with closing expected to take place on or about
View HTML
Toggle Summary ERYTECH Announces Launch of Investigator-Initiated Phase 2 Study of eryaspase (GRASPA®) for ALL
LYON, France --(BUSINESS WIRE)--Apr. 4, 2017-- Regulatory News : ERYTECH Pharma (Paris:ERYP) (ADR:EYRYY) a French clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced the launch of an
View HTML
More >>

Upcoming Events

Date Event Details
Summary Toggle Jun 26, 2020 at 2:00 PM CEST

Annual General Meeting

Summary Toggle Sep 21, 2020

Business Update and Financial Highlights for the 2nd Quarter of 2020 (after U.S. market close)

Summary Toggle Sep 22, 2020 at 8:30 AM EDT

Erytech Pharma 2nd Quarter of 2020 Conference Call and Webcast

RECEIVE E-MAIL ALERTS

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Top